Fig. 5
From: Identification and validation of a refined CAF-Associated diagnostic signature in breast cancer
Drug Sensitivity prediction for luminal and non-luminal CAFs. luminal and non-luminal CAFs were subjected to dimensional reduction and clustering respectively, based on Beyondcell scores of individual cells. (A) UMAP plots present two views: the left depicting TC clusters specific to Luminal CAFs, the right illustrating the distribution patterns of Luminal iCAFs and Luminal mCAFs. (B) Top differential sensitivity drugs of Luminal iCAFs and mCAFs. (C) Intersection of high sensitivity drugs for Luminal mCAFs and low sensitivity drugs for Luminal iCAFs. (D) UMAP plots show top 5 high sensitivity drugs for Luminal mCAFs. (E) Intersection of high sensitivity drugs for Luminal iCAFs and low sensitivity drugs for Luminal mCAFs. (F) UMAP plots show top 5 high sensitivity drugs for Luminal iCAFs. (G) UMAP plots present two views: the left depicting TC clusters specific to non-Luminal CAFs, the right illustrating the distribution patterns of non-Luminal iCAFs and non-Luminal mCAFs. (H) Top differential sensitivity drugs of Luminal iCAFs and mCAFs. (I) Intersection of high sensitivity drugs for non-Luminal mCAFs and low sensitivity drugs for non-Luminal iCAFs. (J) UMAP plots show top 5 high sensitivity drugs for non-Luminal mCAFs. (K) Intersection of high sensitivity drugs for non-Luminal iCAFs and low sensitivity drugs for non-Luminal mCAFs. (L) UMAP plots show top 5 high sensitivity drugs for non-Luminal iCAFs.
